The CADTH pan-Canadian Oncology Drug Review (pCODR) undertakes rigorous, objective reviews of cancer drugs and provides funding recommendations to Canada’s provinces and territories (except Quebec). Funders use this information as one element of their decision-making process to determine if a drug will be eligible for public reimbursement.
pCODR takes into account evidence from a number of sources, including patient groups, submitters (drug manufacturers or provincial clinician-based tumour groups), the pCODR Provincial Advisory Group and, since 2016, registered clinicians.
Input from registered clinicians (practising oncologists or physicians who treat cancer patients, oncology pharmacists, oncology nurses) is collected to gain insight into local clinical practices and identify areas of unmet need. Oncologists or physicians who treat cancer patients can provide their input as an individual submission or jointly in a group submission. Oncology pharmacists and oncology nurses provide invaluable information on drug preparation and administration, and are eligible to provide input as part of a joint submission with a lead oncologist.
The clinician input is incorporated into the pCODR process in a formal and meaningful way. The clinician input is used by the pCODR Expert Review Committee (pERC) — a CADTH advisory body — to provide reimbursement recommendations and advice to provincial and territorial public drug plans (with the exception of Quebec), and to provincial cancer agencies.
As a starting point, clinicians may wish to consult our FAQs sheet on clinician input and feedback to determine their eligibility to participate, and to understand the process. Clinicians must register by visiting the pCODR Registration page. Registered clinicians will receive notifications of upcoming reviews and have access to our secure Collaborative Workspaces to electronically submit their input and feedback to the pCODR program in a secure manner.
Please note that only those registered clinicians who provided input for use in the preparation of the guidance reports early in the process will be eligible to provide feedback on the pERC Initial Recommendation for pERC reconsideration purposes.